Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients.

Gluconeogenesis (GNG) is enhanced in type 2 diabetes. In experimental animals, insulin at high doses decreases the incorporation of labeled GNG precursors into plasma glucose. Whether physiological hyperinsulinemia has any effect on total GNG in humans has not been determined. We combined the insulin clamp with the (2)H(2)O technique to measure total GNG in 33 subjects with type 2 diabetes (BMI 29.0 +/- 0.6 kg/m(2), fasting plasma glucose 8.1 +/- 0.3 mmol/l) and in 9 nondiabetic BMI-matched subjects after 16 h of fasting and after euglycemic hyperinsulinemia. A primed-constant infusion of 6,6-(2)H-glucose was used to monitor endogenous glucose output (EGO); insulin (40 mU. min(-1). m(-2)) was then infused while clamping plasma glucose for 2 h (at 5.8 +/- 0.1 and 4.9 +/- 0.2 mmol/l for diabetic and control subjects, respectively). In the fasting state, EGO averaged 15.2 +/- 0.4 micromol. min(-1). kg(-1)(ffm) (62% from GNG) in diabetic subjects and 12.2 +/- 0.7 micromol. min(-1). kg(-1)(ffm) (55% from GNG) in control subjects (P < 0.05 or less for both fluxes). Glycogenolysis (EGO - GNG) was similar in the two groups (P = NS). During the last 40 min of the clamp, both EGO and GNG were significantly (P < 0.01 or less, compared with fasting) inhibited (EGO 7.1 +/- 0.9 and 3.6 +/- 0.5 and GNG 7.9 +/- 0.5 and 4.5 +/- 1.0 respectively) but remained significantly (P < 0.05) higher in diabetic subjects, whereas glycogenolysis was suppressed completely and equally in both groups. During hyperinsulinemia, GNG micromol. min(-1). kg(-1)(ffm) in diabetic and control subjects, was reciprocally related to plasma glucose clearance. In conclusion, physiological hyperinsulinemia suppresses GNG by approximately 20%, while completely blocking glycogenolysis. Resistance of GNG (to insulin suppression) and resistance of glucose uptake (to insulin stimulation) are coupled phenomena. In type 2 diabetes, the excess GNG of the fasting state is carried over to the insulinized state, thereby contributing to glucose overproduction under both conditions.

[1]  L. Groop,et al.  Determinants of postabsorptive endogenous glucose output in non-diabetic subjects , 2000, Diabetologia.

[2]  E. Ferrannini,et al.  Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. , 2000, Diabetes.

[3]  P. Garlick,et al.  Regulation of splanchnic and renal substrate supply by insulin in humans. , 2000, Metabolism: clinical and experimental.

[4]  G. Shulman,et al.  Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. , 2000, Diabetes.

[5]  M. Jensen,et al.  Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity. , 2000, Diabetes.

[6]  M. Haymond,et al.  The reciprocal pool model for the measurement of gluconeogenesis by use of [U-(13)C]glucose. , 2000, American journal of physiology. Endocrinology and metabolism.

[7]  G. Shulman,et al.  Cellular mechanisms of insulin resistance in humans. , 1999, The American journal of cardiology.

[8]  A. Cherrington,et al.  Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. , 1999, Diabetes.

[9]  K. Petersen,et al.  Contributions of net hepatic glycogenolysis and gluconeogenesis to glucose production in cirrhosis. , 1999, The American journal of physiology.

[10]  G. Boden,et al.  The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. , 1999, The Journal of clinical investigation.

[11]  G. Marchesini,et al.  Quantification of gluconeogenesis in cirrhosis: response to glucagon. , 1998, Gastroenterology.

[12]  K. Petersen,et al.  Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. , 1998, The Journal of clinical investigation.

[13]  R. Wolfe,et al.  Metabolic interactions between glucose and fatty acids in humans. , 1998, The American journal of clinical nutrition.

[14]  J. Wahren,et al.  Quantifying gluconeogenesis during fasting. , 1997, The American journal of physiology.

[15]  J. Wahren,et al.  Contributions of gluconeogenesis to glucose production in the fasted state. , 1996, The Journal of clinical investigation.

[16]  M. Beylot,et al.  Assay of the deuterium enrichment of water via acetylene. , 1996, Journal of mass spectrometry : JMS.

[17]  L. Groop,et al.  7 Insulin action and substrate competition , 1993 .

[18]  L. Groop,et al.  Insulin action and substrate competition. , 1993, Bailliere's clinical endocrinology and metabolism.

[19]  A Mari,et al.  Estimation of the rate of appearance in the non-steady state with a two-compartment model. , 1992, The American journal of physiology.

[20]  Robert R. Wolfe,et al.  Radioactive and Stable Isotope Tracers in Biomedicine: Principles and Practice of Kinetic Analysis , 1992 .

[21]  M. Vranic,et al.  Mild type II diabetes markedly increases glucose cycling in the postabsorptive state and during glucose infusion irrespective of obesity. , 1988, The Journal of clinical investigation.

[22]  W. Clarke,et al.  Methods in diabetes research , 1984 .

[23]  J. Chiasson,et al.  Differential Sensitivity of Glycogenolysis and Gluconeogenesis to Insulin Infusions in Dogs , 1976, Diabetes.

[24]  R Hume,et al.  Prediction of lean body mass from height and weight , 1966, Journal of clinical pathology.